Compare Abbott Laboratories (ABT) vs First Citizens BancShares Inc (FCNCA) Price & Performance

Abbott Laboratories (ABT) trades at $111.27, up 1.39% on the day, with strong analyst support (76% buy ratings) and a consensus price target of $120.70. The stock shows bullish technical momentum with recent earnings beats in Q1 and Q2 2026, though Q4 2025 missed expectations. Revenue growth remains steady at $44.33B for 2025, with solid profitability metrics including 56.61% gross margin and 11.65% net income margin. Recent corporate developments include CE Mark approval for innovative dual glucose-ketone sensors and positive ACS guideline updates for Cologuard cancer screening.

The outlook remains positive with Wall Street consensus favoring accumulation, though risks include potential earnings volatility and competitive pressures in medical technology. The current valuation at 35.89 P/E appears reasonable given the company's innovation pipeline and market leadership. Upside potential exists toward the $120-134 analyst target range, supported by strong cash flow generation and dividend stability.

First Citizens BancShares (FCNCA) trades at $2,271.31, up 0.81% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with a 12.19 P/E ratio, 25.23% net income margin, and consistent earnings beats in recent quarters. Recent business developments include expansion of commercial lending operations and strategic real estate acquisitions, supporting growth initiatives.

FCNCA presents a mixed outlook with strong earnings performance and reasonable valuation offset by cautious analyst sentiment. While technical indicators suggest continued upside potential, the 81.82% hold rating from analysts indicates concerns about valuation and deposit risks. Key opportunities include expanding commercial banking services, while risks center on net interest margin pressure and elevated uninsured deposits at 38.3%.